9 Facts About Vitamin K2 and Why It Matters Specifically in Menopause
When bone density first came up at a routine check, the instinct was to reach for calcium supplements immediately. But the more the research was dug into, the clearer it became that calcium without K2 is a bit like putting fuel in a car with no steering — it can end up somewhere you really don't want it. That reframing changed everything about how to think about midlife nutrition.
Learn more about Rose →K2 Is Not the Same as K1 — and the Difference Is Significant
Vitamin K1 (phylloquinone) is found in leafy greens and is primarily involved in blood clotting, handled mostly by the liver. Vitamin K2 (menaquinone) is found in fermented foods and certain animal products, and it works in soft tissues and bone — a completely different job in a completely different location. Treating them as interchangeable is one of the most common misunderstandings in nutrition, and it means K2 deficiency can exist even in women eating plenty of greens.
Two Proteins Are at the Heart of K2's Role — and Both Depend on It Completely
Osteocalcin is a protein made by bone-building cells (osteoblasts) that can only bind calcium and mineralise bone tissue once it has been activated — carboxylated — by vitamin K2. Matrix Gla Protein (MGP) is the body's most potent inhibitor of arterial calcification, and it too requires K2 to function. Without sufficient K2, both proteins circulate in their inactive, ineffective forms, leaving bones under-mineralised and arteries more vulnerable to calcium deposits.
Menopause Accelerates Bone Loss at Exactly the Moment K2 Demand Increases
Oestrogen plays a direct role in suppressing the bone-resorbing cells called osteoclasts; when oestrogen falls at menopause, osteoclast activity rises and bone turnover accelerates dramatically. The first five to seven years post-menopause carry the steepest bone density decline — roughly 2–3% per year in some women — which is precisely when osteocalcin activation via K2 becomes most critical. Adequate K2 supports the bone-building side of that equation, though it works best as part of a broader bone health strategy.
Cardiovascular Risk Rises After Menopause — and Arterial Calcification Is Part of That Story
Before menopause, oestrogen has a protective effect on blood vessel walls, helping to keep them flexible and reducing inflammatory damage. After menopause, cardiovascular disease risk rises steeply and within a decade becomes the leading cause of death in women. Arterial calcification — the depositing of calcium into artery walls and plaques — is an independent risk factor for cardiovascular events, and this is precisely where K2-activated MGP does its protective work.
MK-7 Is the Form of K2 That Stays Active Longest in the Body
Vitamin K2 comes in several subtypes called menaquinones, numbered MK-4 through MK-13. MK-7, derived from the fermented soy food natto, has the longest half-life in the body — around 72 hours compared to MK-4's few hours — meaning it remains available to activate osteocalcin and MGP for much longer after a single dose. Most of the clinical research supporting K2's role in bone and cardiovascular health has used MK-7, which is why it appears most often in nutrition discussions around menopause.
K2 and Vitamin D3 Work as a Team — Neither Does the Full Job Alone
Vitamin D3 dramatically increases intestinal absorption of calcium and stimulates the production of osteocalcin in bone cells. But producing more osteocalcin is only useful if K2 is present to activate it; without K2, that extra osteocalcin sits idle and the absorbed calcium has nowhere well-directed to go. This is why the D3-and-K2 pairing has become a standard recommendation in bone health research — they are genuinely interdependent, and supplementing one heavily without the other may be an incomplete strategy.
Food Sources of K2 Are Limited and Often Absent From Western Diets
Natto (fermented soybeans) is by far the richest dietary source of MK-7, but it is rarely consumed in Western countries. Smaller amounts of various menaquinone forms appear in hard cheeses, egg yolks, butter from grass-fed animals, chicken liver, and some fermented foods. The practical reality is that most women in the UK, US, and Europe consume very little K2 through food alone — making this one of the few nutrients where supplementation has a logical dietary rationale rather than being redundant for those eating broadly well.
There Is Genuine Clinical Trial Evidence for K2 in Bone Density — Not Just Theory
A three-year randomised controlled trial published in Osteoporosis International (Knapen et al., 2013) found that postmenopausal women taking 180mcg of MK-7 daily had significantly less age-related decline in bone mineral density and bone strength compared to those taking placebo. Importantly, the group taking K2 also showed reduced arterial stiffness — a cardiovascular marker — suggesting the dual bone-and-artery benefit seen in observational data may have a real clinical basis. This is one of the stronger pieces of evidence supporting K2 supplementation specifically in postmenopausal women.
K2 Is Generally Safe but Has One Important Interaction Worth Knowing
For most women, vitamin K2 at typical supplemental doses (90–360mcg of MK-7) appears well tolerated with no significant adverse effects reported in trials to date. The key exception is women taking warfarin (coumadin) or other vitamin K antagonist anticoagulants — K2 can counteract the drug's mechanism, and any change in K2 intake requires medical supervision and INR monitoring. Women on other anticoagulants or with clotting disorders should always check with their GP before starting K2, but for the majority this is not a barrier.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.